34-Year-Old-Man Presents With Acute Appendicitis

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

HER2DX demonstrated the ability to select patients who are more likely to achieve disease control with anti-HER2 standard of care in the CLEOPATRA trial.

Jessica Cheng, MD

September 9th 2024

Initial Staging for PDAC Yields Inaccuracies

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Research shows that patients with pancreatic ductal adenocarcinoma are frequently understaged prior to surgery.

Harrison Widelitz

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Research shows that patients with pancreatic ductal adenocarcinoma are frequently understaged prior to surgery.

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Chris Ryan

Novel PI3Kα Inhibitor Combo Shows Meaningful PFS in HR+/HER2– Breast Cancer

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Treatment with RLY-2608 plus fulvestrant appears well tolerated among patients with PI3Kα-mutated breast cancer in the ReDiscover trial.

Russ Conroy

HER2 Gene Test Predicts Long-Term Pertuzumab Combo PFS/OS in Breast Cancer

Treatment with RLY-2608 plus fulvestrant appears well tolerated among patients with PI3Kα-mutated breast cancer in the ReDiscover trial.

Related Content

Russ Conroy;Ariana Pelosci

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

HER2DX demonstrated the ability to select patients who are more likely to achieve disease control with anti-HER2 standard of care in the CLEOPATRA trial.

Jessica Cheng, MD

September 9th 2024

Initial Staging for PDAC Yields Inaccuracies

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Harrison Widelitz

Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Research shows that patients with pancreatic ductal adenocarcinoma are frequently understaged prior to surgery.

Rahul Banerjee, MD, FACP;Noopur Raje, MD

September 2nd 2024

Valemetostat Shows Meaningful Benefit in Peripheral T-Cell Lymphoma

Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

Chris Ryan

Novel PI3Kα Inhibitor Combo Shows Meaningful PFS in HR+/HER2– Breast Cancer

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Russ Conroy